


**University of Maryland
Marlene and Stewart Greenebaum Cancer Center
Maryland State Council on Cancer
November 12, 2008**


UMGCC Mission

The mission of the UMGCC is to undertake innovative basic and clinical research that will impact the understanding and treatment of cancer around the world and to provide state-of-the-art clinical care to cancer patients in Maryland and beyond.

Critical Recent Milestones in the Cancer Center



Critical Recent Milestones in the Cancer Center



**UMGCC ranked
among the nation's
top 50 cancer centers**



U.S. News & World Report,
America's Best Hospitals 2008

UMGCC at a Glance (2008)

- 3 Research Programs + 2 Developing
- 4 Shared Services + 4 Developing
- 158 Members (122 Full, 36 Assoc)
- NCI Total Funding \$15.4M
- Total Cancer Funding \$48.7M
- 211 Clinical Trials (946 pts total, 242 therapeutic - 36% under-represented minorities)




University of Maryland School of Medicine



Programs & Shared Services

3 Programs
4 Shared Services

2 Developing Programs
4 Developing Shared Services



Growth in Grant Funding 2002 - 2008

FUNDING AGENCY/ SOURCE	PROJECTS			DIRECT COSTS			TOTAL COSTS		
	2002	2007	2008	2002	2007	2008	2002	2007	2008
NCI	37	72	69	6,491	10,113	10,776	9,262	14,431	15,480
OTHER NIH	20	64	64	3,517	8,995	8,951	4,965	11,963	12,766
OTHER PEER REVIEWED	35	31	40	4,226	2,434	3,787	5,273	3,684	3,737
SUBTOTAL OF PEER REVIEWED	92	167	173	14,234	22,132	23,514	19,500	30,079	31,983
NON PEER-REVIEWED	30	88	73	5,236	16,835	15,762	6,242	18,078	16,711
GRAND TOTAL (ALL PROJECTS)	122	255	246	19,470	38,968	39,276	25,742	48,156	48,694

UMGCC 2008


- Remarkable growth; outstanding faculty and staff; extremely strong state, institutional and philanthropic support
- High impact research in breast cancer and other areas which has changed cancer care worldwide
- Unique ability to understand and impact cancer disparities through clinical and basic research

Strategic Plan 2008-2011

Goals

- Increase research funding (esp NCI)
- Increase clinical/clinical research activity
- Establish developing programs and shared services with goal of 5 full programs and 6 services by 2011
- Expand emphasis on cancer disparities
- Fulfill NCI Cancer Center designation and obtain comprehensive status

Head and Neck Cancer - UMGCC



Source: Dr. K Settle

Recruitment/Development Priorities

- Viral Oncology
- Immunology
- Epidemiology (new division of cancer epidemiology, will be integrated with Viral Oncology efforts)
 - In all areas, maintain and increase strong focus on cancer disparities

Tumor Immunology and Immunotherapy

■ Leader

- Scott Strome, M.D., Chair Dept of Otorhinolaryngology

■ Aims

- Develop and characterize the molecular and immunologic function of molecules which can be employed to manipulate the innate and adaptive immune response to malignancy
- Design preventive and therapeutic trials for defined select cancers, utilizing molecules that can be employed to manipulate the innate and adaptive immune responses to malignancy
- Monitor clinical and immunologic responses to both immuno and conventional therapeutics

Viral Oncology

■ Leaders

- ❑ Robert Gallo, M.D. Director, Inst. For Human Virology
- ❑ David Pauza, Ph.D (Replaces Marvin Reitz)

■ Aims

- ❑ Determine mechanisms by which viruses contribute directly to tumor formation and maintenance
- ❑ Determine the roles that altered immunity, especially in the setting of HIV infection play in tumor formation and maintenance
- ❑ Elucidate mechanism by which HIV cooperates with other viruses to facilitate tumorigenesis

Epidemiology

■ Leaders

- Bill Blattner, M.D., Institute of Human Virology
- TBN Division Chief/Associate Director for population science

■ Aims

- Establish strong Division of Cancer Epidemiology
- Establish field epidemiology presence in Africa
- Elucidate mechanism by which HIV cooperates with other viruses to facilitate tumorigenesis